Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 2.40
HALO's Cash-to-Debt is ranked lower than
70% of the 1078 Companies
in the Global Biotechnology industry.

( Industry Median: 64.02 vs. HALO: 2.40 )
Ranked among companies with meaningful Cash-to-Debt only.
HALO' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.84  Med: No Debt Max: No Debt
Current: 2.4
0.84
No Debt
Equity-to-Asset 0.54
HALO's Equity-to-Asset is ranked lower than
67% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. HALO: 0.54 )
Ranked among companies with meaningful Equity-to-Asset only.
HALO' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.65  Med: 0.29 Max: 0.97
Current: 0.54
-1.65
0.97
Debt-to-Equity 0.65
HALO's Debt-to-Equity is ranked lower than
73% of the 500 Companies
in the Global Biotechnology industry.

( Industry Median: 0.28 vs. HALO: 0.65 )
Ranked among companies with meaningful Debt-to-Equity only.
HALO' s Debt-to-Equity Range Over the Past 10 Years
Min: -17.7  Med: 0.98 Max: 20.98
Current: 0.65
-17.7
20.98
Debt-to-EBITDA 1.70
HALO's Debt-to-EBITDA is ranked higher than
56% of the 196 Companies
in the Global Biotechnology industry.

( Industry Median: 2.04 vs. HALO: 1.70 )
Ranked among companies with meaningful Debt-to-EBITDA only.
HALO' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.73  Med: -0.72 Max: 2.36
Current: 1.7
-2.73
2.36
Interest Coverage 4.30
HALO's Interest Coverage is ranked lower than
92% of the 500 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. HALO: 4.30 )
Ranked among companies with meaningful Interest Coverage only.
HALO' s Interest Coverage Range Over the Past 10 Years
Min: 3.68  Med: No Debt Max: No Debt
Current: 4.3
3.68
No Debt
Piotroski F-Score: 7
Altman Z-Score: 7.44
Beneish M-Score: 1.61
WACC vs ROIC
20.83%
-535.83%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 28.25
HALO's Operating Margin % is ranked higher than
92% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -113.97 vs. HALO: 28.25 )
Ranked among companies with meaningful Operating Margin % only.
HALO' s Operating Margin % Range Over the Past 10 Years
Min: -575.48  Med: -105.19 Max: 28.25
Current: 28.25
-575.48
28.25
Net Margin % 23.88
HALO's Net Margin % is ranked higher than
91% of the 792 Companies
in the Global Biotechnology industry.

( Industry Median: -111.91 vs. HALO: 23.88 )
Ranked among companies with meaningful Net Margin % only.
HALO' s Net Margin % Range Over the Past 10 Years
Min: -555.16  Med: -108.65 Max: 23.88
Current: 23.88
-555.16
23.88
ROE % 44.40
HALO's ROE % is ranked higher than
97% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -42.82 vs. HALO: 44.40 )
Ranked among companies with meaningful ROE % only.
HALO' s ROE % Range Over the Past 10 Years
Min: -1958.98  Med: -284.98 Max: 71.6
Current: 44.4
-1958.98
71.6
ROA % 17.40
HALO's ROA % is ranked higher than
96% of the 1084 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. HALO: 17.40 )
Ranked among companies with meaningful ROA % only.
HALO' s ROA % Range Over the Past 10 Years
Min: -75.94  Med: -52.25 Max: 17.4
Current: 17.4
-75.94
17.4
ROC (Joel Greenblatt) % 829.73
HALO's ROC (Joel Greenblatt) % is ranked higher than
98% of the 1036 Companies
in the Global Biotechnology industry.

( Industry Median: -521.46 vs. HALO: 829.73 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
HALO' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2382.35  Med: -961.94 Max: 829.73
Current: 829.73
-2382.35
829.73
3-Year Revenue Growth Rate 54.80
HALO's 3-Year Revenue Growth Rate is ranked higher than
89% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. HALO: 54.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
HALO' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 37.5 Max: 232.2
Current: 54.8
0
232.2
GuruFocus has detected 3 Warning Signs with Halozyme Therapeutics Inc HALO.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» HALO's 30-Y Financials

Financials (Next Earnings Date: 2018-11-07 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2017

HALO Guru Trades in Q3 2017

Louis Moore Bacon Sold Out
John Paulson Sold Out
Ken Fisher 583,221 sh (-5.02%)
First Eagle Investment 6,444,981 sh (-12.84%)
Murray Stahl 23,607 sh (-22.93%)
Paul Tudor Jones 18,765 sh (-59.30%)
» More
Q4 2017

HALO Guru Trades in Q4 2017

Jim Simons 736,600 sh (New)
Paul Tudor Jones 30,637 sh (+63.27%)
Ken Fisher 560,373 sh (-3.92%)
Murray Stahl 19,208 sh (-18.63%)
First Eagle Investment 4,531,081 sh (-29.70%)
» More
Q1 2018

HALO Guru Trades in Q1 2018

Joel Greenblatt 115,942 sh (New)
Jim Simons 893,400 sh (+21.29%)
Murray Stahl 19,272 sh (+0.33%)
Ken Fisher 498,014 sh (-11.13%)
First Eagle Investment 3,004,753 sh (-33.69%)
Paul Tudor Jones 17,373 sh (-43.29%)
» More
Q2 2018

HALO Guru Trades in Q2 2018

Murray Stahl 21,680 sh (+12.49%)
Paul Tudor Jones Sold Out
Jim Simons 878,400 sh (-1.68%)
Ken Fisher 453,652 sh (-8.91%)
First Eagle Investment 2,124,563 sh (-29.29%)
Joel Greenblatt 62,201 sh (-46.35%)
» More
» Details

Insider Trades

Latest Guru Trades with HALO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
First Eagle Investment 2018-06-30 Reduce -29.29%0.04%$16.87 - $20.3 $ 17.53-7%2,124,563
Ken Fisher 2018-06-30 Reduce -8.91%$16.87 - $20.3 $ 17.53-7%453,652
Joel Greenblatt 2018-06-30 Reduce -46.35%0.01%$16.87 - $20.3 $ 17.53-7%62,201
First Eagle Investment 2018-03-31 Reduce -33.69%0.07%$17.06 - $21.2 $ 17.53-9%3,004,753
Ken Fisher 2018-03-31 Reduce -11.13%$17.06 - $21.2 $ 17.53-9%498,014
Joel Greenblatt 2018-03-31 New Buy0.03%$17.06 - $21.2 $ 17.53-9%115,942
First Eagle Investment 2017-12-31 Reduce -29.70%0.07%$16.75 - $20.8 $ 17.53-5%4,531,081
Ken Fisher 2017-12-31 Reduce -3.92%$16.75 - $20.8 $ 17.53-5%560,373
First Eagle Investment 2017-09-30 Reduce -12.84%0.03%$11.76 - $17.4 $ 17.5330%6,444,981
Ken Fisher 2017-09-30 Reduce -5.02%$11.76 - $17.4 $ 17.5330%583,221
John Paulson 2017-09-30 Sold Out 0.02%$11.76 - $17.4 $ 17.5330%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:NAS:IMMU, XBRU:ARGX, XSWX:IDIA, SZSE:000990, SHSE:600161, NAS:TSRO, NAS:ONCE, NAS:ARRY, SZSE:002603, NAS:CBPO, XSWX:GALE, NAS:ASND, NAS:FOLD, NYSE:EBS, ROCO:4147, NAS:RARE, NAS:PBYI, XTER:MOR, SZSE:002821, SZSE:300009 » details
Traded in other countries:RV7.Germany,
Headquarter Location:USA
Halozyme Therapeutics Inc is a biotechnology company. It is engaged in research on human enzymes that alter the extracellular matrix and tumor environment.

Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Guru Investment Theses on Halozyme Therapeutics Inc

First Eagle Fund of America Comments on Halozyme Therapeutics - Oct 31, 2017

Halozyme Therapeutics (NASDAQ:HALO) announced new licensing agreements with Roche and with Bristol-Myers-Squibb for its ENHANZE drug-delivery technology. Following these agreements, which include upfront and milestone payments, as well as long-term royalty streams, Halozyme increased its cash-balance guidance for the year. Halozyme has two main parts to its business: a drug-delivery technology that has been profitable and growing, and a proprietary exploratory oncology pipeline.



From First Eagle Fund of America third quarter 2017 shareholder commentary.



Check out First Eagle Investment latest stock trades

Ratios

vs
industry
vs
history
PE Ratio 30.74
HALO's PE Ratio is ranked lower than
51% of the 248 Companies
in the Global Biotechnology industry.

( Industry Median: 28.79 vs. HALO: 30.74 )
Ranked among companies with meaningful PE Ratio only.
HALO' s PE Ratio Range Over the Past 10 Years
Min: 28.99  Med: 37.8 Max: 47.35
Current: 30.74
28.99
47.35
PE Ratio without NRI 30.74
HALO's PE Ratio without NRI is ranked lower than
51% of the 243 Companies
in the Global Biotechnology industry.

( Industry Median: 28.64 vs. HALO: 30.74 )
Ranked among companies with meaningful PE Ratio without NRI only.
HALO' s PE Ratio without NRI Range Over the Past 10 Years
Min: 28.99  Med: 37.8 Max: 47.35
Current: 30.74
28.99
47.35
Price-to-Owner-Earnings 32.35
HALO's Price-to-Owner-Earnings is ranked higher than
54% of the 145 Companies
in the Global Biotechnology industry.

( Industry Median: 34.35 vs. HALO: 32.35 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
HALO' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 28.92  Med: 33.15 Max: 36.95
Current: 32.35
28.92
36.95
PB Ratio 9.95
HALO's PB Ratio is ranked lower than
79% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. HALO: 9.95 )
Ranked among companies with meaningful PB Ratio only.
HALO' s PB Ratio Range Over the Past 10 Years
Min: 7.06  Med: 26.64 Max: 148.72
Current: 9.95
7.06
148.72
PS Ratio 8.09
HALO's PS Ratio is ranked higher than
60% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. HALO: 8.09 )
Ranked among companies with meaningful PS Ratio only.
HALO' s PS Ratio Range Over the Past 10 Years
Min: 6.77  Med: 20.53 Max: 235.25
Current: 8.09
6.77
235.25
Price-to-Free-Cash-Flow 20.76
HALO's Price-to-Free-Cash-Flow is ranked higher than
68% of the 152 Companies
in the Global Biotechnology industry.

( Industry Median: 37.07 vs. HALO: 20.76 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
HALO' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 19.58  Med: 22.51 Max: 30.16
Current: 20.76
19.58
30.16
Price-to-Operating-Cash-Flow 20.35
HALO's Price-to-Operating-Cash-Flow is ranked higher than
65% of the 210 Companies
in the Global Biotechnology industry.

( Industry Median: 29.99 vs. HALO: 20.35 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
HALO' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 19.2  Med: 23.02 Max: 1792.5
Current: 20.35
19.2
1792.5
EV-to-EBIT 24.05
HALO's EV-to-EBIT is ranked lower than
53% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 22.17 vs. HALO: 24.05 )
Ranked among companies with meaningful EV-to-EBIT only.
HALO' s EV-to-EBIT Range Over the Past 10 Years
Min: -99.9  Med: -13.5 Max: 33.9
Current: 24.05
-99.9
33.9
EV-to-EBITDA 23.39
HALO's EV-to-EBITDA is ranked lower than
56% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 18.08 vs. HALO: 23.39 )
Ranked among companies with meaningful EV-to-EBITDA only.
HALO' s EV-to-EBITDA Range Over the Past 10 Years
Min: -105.6  Med: -13.8 Max: 33.1
Current: 23.39
-105.6
33.1
EV-to-Revenue 7.14
HALO's EV-to-Revenue is ranked higher than
66% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 13.69 vs. HALO: 7.14 )
Ranked among companies with meaningful EV-to-Revenue only.
HALO' s EV-to-Revenue Range Over the Past 10 Years
Min: 6.5  Med: 19.65 Max: 212.9
Current: 7.14
6.5
212.9
Current Ratio 3.49
HALO's Current Ratio is ranked lower than
59% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. HALO: 3.49 )
Ranked among companies with meaningful Current Ratio only.
HALO' s Current Ratio Range Over the Past 10 Years
Min: 1.81  Med: 5.83 Max: 41
Current: 3.49
1.81
41
Quick Ratio 3.43
HALO's Quick Ratio is ranked lower than
57% of the 1074 Companies
in the Global Biotechnology industry.

( Industry Median: 4.18 vs. HALO: 3.43 )
Ranked among companies with meaningful Quick Ratio only.
HALO' s Quick Ratio Range Over the Past 10 Years
Min: 1.81  Med: 5.57 Max: 41
Current: 3.43
1.81
41
Days Inventory 157.22
HALO's Days Inventory is ranked lower than
61% of the 481 Companies
in the Global Biotechnology industry.

( Industry Median: 125.55 vs. HALO: 157.22 )
Ranked among companies with meaningful Days Inventory only.
HALO' s Days Inventory Range Over the Past 10 Years
Min: 99.19  Med: 254.5 Max: 936.48
Current: 157.22
99.19
936.48
Days Sales Outstanding 38.38
HALO's Days Sales Outstanding is ranked higher than
73% of the 668 Companies
in the Global Biotechnology industry.

( Industry Median: 64.17 vs. HALO: 38.38 )
Ranked among companies with meaningful Days Sales Outstanding only.
HALO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 14.72  Med: 61.48 Max: 302.53
Current: 38.38
14.72
302.53
Days Payable 114.59
HALO's Days Payable is ranked higher than
65% of the 536 Companies
in the Global Biotechnology industry.

( Industry Median: 63.91 vs. HALO: 114.59 )
Ranked among companies with meaningful Days Payable only.
HALO' s Days Payable Range Over the Past 10 Years
Min: 39.33  Med: 470.62 Max: 10691.1
Current: 114.59
39.33
10691.1

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -4.30
HALO's 3-Year Average Share Buyback Ratio is ranked higher than
78% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -13.40 vs. HALO: -4.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
HALO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -244.9  Med: -8.7 Max: -4.2
Current: -4.3
-244.9
-4.2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 14.14
HALO's Price-to-Net-Cash is ranked lower than
70% of the 613 Companies
in the Global Biotechnology industry.

( Industry Median: 7.29 vs. HALO: 14.14 )
Ranked among companies with meaningful Price-to-Net-Cash only.
HALO' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 6.5  Med: 26.21 Max: 288.5
Current: 14.14
6.5
288.5
Price-to-Net-Current-Asset-Value 10.43
HALO's Price-to-Net-Current-Asset-Value is ranked lower than
66% of the 745 Companies
in the Global Biotechnology industry.

( Industry Median: 6.45 vs. HALO: 10.43 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
HALO' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 6.07  Med: 24.83 Max: 546
Current: 10.43
6.07
546
Price-to-Tangible-Book 9.90
HALO's Price-to-Tangible-Book is ranked lower than
73% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: 5.32 vs. HALO: 9.90 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
HALO' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 6.03  Med: 23.52 Max: 116.17
Current: 9.9
6.03
116.17
Price-to-Median-PS-Value 0.40
HALO's Price-to-Median-PS-Value is ranked higher than
84% of the 678 Companies
in the Global Biotechnology industry.

( Industry Median: 0.92 vs. HALO: 0.40 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
HALO' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.36  Med: 1.31 Max: 92
Current: 0.4
0.36
92
Price-to-Graham-Number 3.68
HALO's Price-to-Graham-Number is ranked lower than
64% of the 200 Companies
in the Global Biotechnology industry.

( Industry Median: 2.27 vs. HALO: 3.68 )
Ranked among companies with meaningful Price-to-Graham-Number only.
HALO' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 3.47  Med: 4.31 Max: 5.39
Current: 3.68
3.47
5.39
Earnings Yield (Greenblatt) % 4.17
HALO's Earnings Yield (Greenblatt) % is ranked higher than
87% of the 1081 Companies
in the Global Biotechnology industry.

( Industry Median: -7.73 vs. HALO: 4.17 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
HALO' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -28  Med: -6.2 Max: 4.44
Current: 4.17
-28
4.44

More Statistics

Revenue (TTM) (Mil) $319.37
EPS (TTM) $ 0.57
Beta3.12
Volatility37.96%
52-Week Range $16.06 - 21.48
Shares Outstanding (Mil)144.30

Analyst Estimate

Dec18 Dec19
Revenue (Mil $) 170 155
EBIT (Mil $)
EBITDA (Mil $)
EPS ($) -0.48 -0.37
EPS without NRI ($) -0.48 -0.37
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 77
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAY
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}